Assessment of total tau protein, phospho-tau and beta amyloid in cerebrospinal fluid: The first experience of our laboratory;Vyšetřování celkového tau proteinu, phospho-tau proteinu a beta-amyloidu v mozkomíšním moku - Naše první zkušenosti

Klinicka Biochemie a Metabolismus

Volumn 12, Issue 2, 2004, Pages 113-116

  Glosová, Libuše ^a,b   Hort, J ^a   Bojar, M ^a   Skoda D ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NONE   (Czech Republic)

Author keywords

Alzheimer's disease; Beta amyloid; Cerebrospinal fluid; Phospho tau protein; Total tau protein

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN PROTEIN; PHOSPHO TAU PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFLAMMATION; NEUROLOGIC DISEASE; PICK PRESENILE DEMENTIA; PREDICTION; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; QUANTITATIVE ANALYSIS;

EID: 2442676391     PISSN: 12107921     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Andreasen, N., Minthon, L., Vanmechelen, E. et al. Cerebrospinal fluid tau and Abeta 42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neuroscience Letters, 1999, 273, p. 5-8.
2. Blennow, K., Vanmechelen, E. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. J. Neural. Transm. Suppl., 1998, 53, p. 223-235.
3. Buerger, K., Zinkowski, R., Teipel, S. et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol., 2002, 59 (8), p. 1267-1272.
4. Du, S., Dodel, R., Hampel, H. et al. Reduced level of amyloid beta-peptide antibody in Alzheimer disease. Neurology, 2001, 11, p. 801-805.
5. Hesse, C., Rosengren, S., Andreasen, N. et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neuroscience Letters, 2001, 297, p. 187-190.
6. Ishiguro, K., Ohno, H., Arai, H. et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neuroscience Letters, 1999, 270, p. 91-94.
7. Kohnken, R., Buerger, K., Zinkowski, R. et al. Detection of tau phosphorylated at 231 in cerebrospinal fluid of Alzheimer's disease patients. Neuroscience Letters, 2000, 287, p. 187-190.
8. Maruyama, M., Arai, H., Sugita, M. et al. Cerebrospinal fluid amyloid beta (1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp. Neurol., 2001, 172 (2), p. 433-436.
9. Nagga, K., Gottfries, J., Blennow, K., Marcusson, J. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid (1-42) in the differenciation between Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn. Disord., 2002, 14 (4), p. 183-190.
10. Sjögren, M., Davidsson, P., Tullberg, M. et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 2001, 70, p. 624-630.